Valneva SE (VALN) fair value analysis
Nasdaq · Updated 2026-10-26
VALN price how computed
Valuation status
Reports in EURVALN reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for VALN until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $5.90
- Sector
- Healthcare
- 12-month range
- $4.78–$11.99
- Market cap
- $559M
- From 52-week high
- -50.8%
- Shares outstanding
- 94.8M
- Rank in Healthcare by quality score
- #300 of 302
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-23.
Valneva SE is a biopharmaceutical company that develops and commercializes vaccines for infectious diseases. The company operates in Europe and has a presence in multiple countries including France and Austria.
VALN currently ranks #300 of 302 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $559M
- Revenue (TTM)
- EUR 144M
- Net margin
- -110.2%
- EPS (TTM)
- EUR -2.09
- Gross margin
- 4.6%
- Debt / equity
- 2.59
- Revenue growth (3-yr avg)
- -2.2%
- Shares outstanding
- 94.8M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 35 · neutral
- 50-day average
- $6.32
- 200-day average
- $6.93
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-19
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-42.9%)
2026-03 ▼ miss (-100.0%)
2025-12 ▼ miss (-81.8%)
2025-09 ▼ miss (-130.8%)
2025-06 ▲ beat (+15.8%)
2025-03 ▲ beat (+71.1%)
2024-12 ▼ miss (-237.5%)
2024-09 ▲ beat (+6.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 0 hold · 1 sell (4 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $12.2
- Target vs last price
- +106.8%
What our data shows for VALN
- Shares are trading in the lower third of their 12-month price range of $4.78–$11.99.
- The 14-day relative strength index sits at a neutral 35.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- VALN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the VALN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-26 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is VALN stock undervalued?
VALN reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for VALN until same-currency inputs are available.
What is VALN's TickrTrends verdict?
VALN is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does VALN compare to other Healthcare stocks?
VALN ranks #300 of 302 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is VALN overbought or oversold?
VALN's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does VALN report earnings next?
VALN's next earnings report is scheduled for 2026-11-19, per the published earnings calendar.
Does VALN usually beat earnings estimates?
Over its last 8 reported quarters VALN beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about VALN?
Of 4 analysts covering VALN, 3 rate it a buy, 0 a hold and 1 a sell - buy-leaning, with a consensus price target of $12.2 (+106.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.